Unituxin Intravenous Infusion 17.5mg / 5mL specific drug use-results survey (Survey of all cases)

JRCT ID: jRCT2031210508

Registered date:23/12/2021

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: neuroblastoma after high-dose chemotherapy
• Date of first enrollment: 23/12/2021
• Target sample size: 120
• Study type: Observational

Outcome(s)

Primary Outcome

Safety
prefecture side effect incidence rate
Prognosis survey
Overall survival rate at 5 years, Information about growth and developmental disorders, Presence or absence of safety considerations

• Secondary Outcome: best overall response

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

All patients receiving Unituxin after September 22, 2021
Patients with neuroblastoma after high-dose chemotherapy

• Exclude criteria: Patients with a history of hypersensitivity to the ingredients of Unituxin

Related Information

• Primary Sponsor: Medicine Development Center PMS unit
• Secondary ID(s): Nil known